# Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

> **NCT01241500** · PHASE3 · COMPLETED · sponsor: **Traws Pharma, Inc.** · enrollment: 299 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- MDS
- RAEB
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** ON 01910.Na

## Key facts

- **NCT ID:** NCT01241500
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2018-10-03
- **Final completion:** 2018-10-03
- **Target enrollment:** 299 (ACTUAL)
- **Last updated:** 2020-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01241500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01241500, "Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01241500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*